What is nivolumab (PD-1 inhibitor)?
Nivolumab is an immune checkpoint inhibitor that targets the PD-1 (programmed death-1) receptor on T cells. By blocking PD-1, it can help the immune system recognize and attack cancer cells.
What cancers is nivolumab used for?
Nivolumab is used to treat several cancers, including (depending on country, indication, and tumor markers) lung cancer, melanoma, kidney cancer, head and neck cancer, classical Hodgkin lymphoma, and cancers with specific biomarkers such as microsatellite instability–high (MSI-H) or mismatch repair deficiency (dMMR).
How is nivolumab given?
Nivolumab is given by intravenous (IV) infusion, typically on a fixed schedule that can vary by regimen and indication.
What are common side effects patients ask about?
Because nivolumab boosts immune activity, side effects often come from immune-related inflammation in different organs. Commonly reported effects include fatigue, skin reactions, nausea, decreased appetite, and diarrhea. Immune-related adverse events can also affect organs such as the lungs, liver, gut, endocrine glands (thyroid/pituitary), and kidneys, and may require treatment interruption and steroids.
How fast does nivolumab work, and how is response judged?
Responses can take time, and in some cases tumors may initially appear to grow before shrinking (a pattern sometimes discussed as “pseudoprogression”). Clinicians typically assess response using imaging over time and also consider symptoms and overall clinical status rather than a single scan alone.
What does “PD-1 inhibitor” mean for treatment strategy?
PD-1 inhibitors like nivolumab are often used:
- After prior therapy (for some cancers),
- As part of first-line treatment in certain settings,
- Or combined with other drugs (commonly other immunotherapies or targeted/chemotherapy regimens), depending on the cancer type and biomarkers.
What are the key risks and monitoring steps?
Patients are monitored for immune-related side effects through clinical checks and lab tests (such as liver enzymes and thyroid function). If immune toxicity occurs, treatment may be paused and managed with steroids or other immunosuppressive therapies.
How does nivolumab compare with other PD-1 inhibitors?
Other PD-1 inhibitors include pembrolizumab and cemiplimab. They work via the same PD-1 pathway but differ in dosing schedules, approved indications, and sometimes combination partners and eligibility criteria.
If you mean “PD-1 inhibitor nivolumab” for a specific cancer, tell me which one
If you share the cancer type (and whether it’s metastatic/resected, and any biomarkers like PD-L1, MSI-H/dMMR, EGFR/ALK status, etc.), I can narrow down the usual indications, typical dosing approaches, and the side-effect profile for that exact situation.